• Users Online: 106
  • Print this page
  • Email this page
  • Email this page
  • Email this page
  • Email this page
Year : 2020  |  Volume : 38  |  Issue : 3  |  Page : 151-158

Amniotic membrane for treating chronic cutaneous ulcers: A systematic review and meta-analysis of randomized controlled trials

1 Department of Dermatology, Maoming People's Hospital, Maoming, Guangdong, China
2 Department of Urology, Maoming People's Hospital, Maoming, Guangdong, China
3 Department of Internal Medicine, Southern Medical University, Guangzhou, China
4 Department of Pulmonary Medicine, Marshall University School of Medicine, Huntington, West Virginia, USA
5 Institute for Hospital Management, Tsinghua University, Shenzhen, China
6 Department of Dermatology, Maoming People's Hospital, Maoming, Guangdong, China; Department of Medical Research and Education, Cheng-Hsin General Hospital, Taipei, Taiwan

Correspondence Address:
Prof. Ching-Wen Chien
Institute for Hospital Management, Tsing Hua University, Shenzhen Campus, Shenzhen
Dr. Tao-Hsin Tung
Department of Medical Research and Education, Cheng Hsin General Hospital, Taipei; Maoming People's Hospital, Maoming, Guangdong

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ds.ds_12_20

Rights and Permissions

Background: In recent years, many studies have reported that amniotic membrane (AM) is an effective adjuvant for promoting the healing of chronic cutaneous ulcers (CCUs). Objectives: The objective of the present study was to evaluate the efficacy and safety of AM for the topical treatment of CCUs. Methods: A literature search was performed using PubMed, Cochrane Library, and Embase for all related studies from inception to May 31, 2019, without restriction on language. A quantitative synthesis of randomized controlled trials (RCTs) was conducted to compare the effectiveness and safety between the AM therapy and standard of care/conventional treatment by employing a random-effect model. Results: Thirteen RCTs with 947 patients were included in the study. Compared to standard of care (SOC), the relative risk (RR) for the healing rate was 1.99 (95% confidence interval [CI]: 1.75–2.26, P < 0.001). A greater percentage area reduction could be found in AM group (mean difference = 70.00%, 95% CI: 15.82–124.17, P = 0.01). There was no statistically significant difference in pain relief (P = 0.36). The RR for adverse events was estimated 0.54 (95% CI: 0.31–0.93) when compared AM group with SOC group (P = 0.03). Conclusion: This systematic review and meta-analysis indicate that it is effective and safe to use AM as an adjuvant treatment for treating CCUs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded275    
    Comments [Add]    

Recommend this journal